Integrated Multidisciplinary Brain Metastasis Care Reduces Patient Visits and Shortens Time to Adjuvant Irradiation
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/op/authors/author-center.
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).
Nelson S. Moss
Consulting or Advisory Role: AstraZeneca
Research Funding: GT Medical Technologies (Inst)
Samantha Brown
Research Funding: AACR (Inst)
Justin Chen
Stock and Other Ownership Interests: MindMed, Moderna Therapeutics, Tonix Pharmaceuticals, Ocugen, Ocuphire Pharma, Innerscope Hearing Technologies, Heat Biologics
Brandon S. Imber
Honoraria: GT Medical Technologies
Luke Pike
Stock and Other Ownership Interests: Clovis Oncology, Schrodinger, Novavax
Consulting or Advisory Role: Blackstone, Deerfield Management, Third Rock Ventures, Aviko, Monograph Capital, Roivant, Galera Therapeutics, Dynamo Therapeutics, Myst Therapeutics, Turnstone Bio, Best Doctors Inc
Katherine S. Panageas
Stock and Other Ownership Interests: AstraZeneca, Pfizer, Sunesis Pharmaceuticals
Cameron Brennan
Stock and Other Ownership Interests: AVEO
Patents, Royalties, Other Intellectual Property: Co-inventor on patents licensed through Memorial Sloan Kettering to Elucida Oncology
Viviane Tabar
Stock and Other Ownership Interests: BlueRock Therapeutics (I)
Honoraria: BlueRock Therapeutics (I)
Consulting or Advisory Role: BlueRock Therapeutics (I)
Research Funding: BlueRock Therapeutics (I)
Patents, Royalties, Other Intellectual Property: BlueRock Therapeutics (I)
Travel, Accommodations, Expenses: BlueRock Therapeutics (I)
Kathryn Beal
Stock and Other Ownership Interests: MMT (I)
No other potential conflicts of interest were reported.
留言 (0)